The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > BUSINESS
BUSINESS
- Merck Serono Obtains Marketing Rights for Cetrotide from Shionogi
April 22, 2013
- AnGes MG, Shionogi to Start PI Study for Nucleic Acid Drug for Atopic Dermatitis
April 19, 2013
- Daiichi Sankyo to Enter Branded Generics Business in Brazil with Launch of 2 Products
April 19, 2013
- Eli Lilly Japan Aims to Be a Top-10 Drug Maker in Japan by 2020, but Re-pricing and Generic Competition Could Pose Obstacles
April 19, 2013
- Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
- Taisho, Nissui Launch Switch OTC Epadel; Prior Doctor Consultation Required for Patients
April 18, 2013
- Meiji Seika Pharma Licenses Schizophrenia Treatment from MSD, to Market It Independently
April 18, 2013
- Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
- Pfizer’s Palbociclib Receives Breakthrough Therapy Designation from US FDA
April 18, 2013
- Teijin, Kyorin Expected to Grow thru “Win-Win” Relationship: Teijin Pharma Pres.
April 17, 2013
- Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
- BMKK Sales Up 13% to 62 Billion Yen in 2012
April 17, 2013
- Nearly 43% of Pharmacies Now Receive Class 3 Fee for Generic Drug Dispensing Systems: Survey
April 17, 2013
- Astellas Appoints Dr Xue as Head of GPV
April 17, 2013
- FDA Accepts Otsuka Tolvaptan NDA for Priority Review
April 17, 2013
- Chugai Voluntarily Recalls Digosin Tablets
April 16, 2013
- Toho Holdings Establishes New Company for Distribution Management of Specialty Drugs
April 16, 2013
- MAA for Lurasidone Accepted in Australia: DSP
April 16, 2013
- Hisamitsu Sales Up 3.6% Helped by Mohrus Tape Sales Recovery
April 15, 2013
- Over Half of Domestic, Foreign-Affiliated Drug Makers Hired Fewer New Graduates This Year: Survey
April 15, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…